Drug Profile
Research programme: neurological disorder therapeutics - Novartis Gene Therapies
Alternative Names: AVXS-301Latest Information Update: 28 May 2023
Price :
$50
*
At a glance
- Originator AveXis
- Developer Novartis Gene Therapies
- Class Gene therapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Friedreich's ataxia
- No development reported Amyotrophic lateral sclerosis
Most Recent Events
- 28 May 2023 No recent reports of development identified for preclinical development in Amyotrophic-lateral-sclerosis in USA (Parenteral)
- 26 May 2021 Preclinical development in Amyotrophic lateral sclerosis is ongoing in USA (Parenteral)
- 28 Feb 2021 No recent reports of development identified for preclinical development in Amyotrophic-lateral-sclerosis in USA (Parenteral)